Dopaminergic projection to the central amygdala mediates the facilitatory effect of CCK-8US and caerulein on memory in rats

Pharmacological Research

Volumn 39, Issue 6, 1999, Pages 445-450

  Winnicka, Maria M ^a   Wiśniewski, Konstanty ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

6 OHDA lesions; CCK 8US; Central amygdala; CER; Passive avoidance; Rats

Indexed keywords

CERULETIDE; CHOLECYSTOKININ OCTAPEPTIDE; OXIDOPAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FACILITATION; LEARNING; MALE; MEMORY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VENTRAL TEGMENTUM;

EID: 0344223288     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0496     Document Type: Article

References (59)

1. Vanderhaeghen J J, Signeau J C, Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature. 257:1975;604-605.
2. Hökfelt T, Rehfeld J F, Skirboll L, Ivemark B, Goldstein M, Markey K. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature (London). 285:1980;476-478.
3. Hökfelt T, Skirboll L, Rehfeld J F, Goldstein M, Markey K, Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 5:1980;2093-2121.
4. Vanderhaeghen J J, Lotstra F, Demey J, Gilles C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. Proc Natl Acad Sci USA. 77:1980;1190-1194.
5. Emson P C, Rehfeld J F, Rossor M N. Distribution of cholecystokinin in the human brain. J Neurochem. 38:1982;1177-1179.
6. Dockray G J. Immunochemical evidence for the cholecystokinin-like peptides in brain. Nature. 264:1976;564-570.
7. Saito A, Sankaran H, Goldfine I D, Williams J A. Cholecystokinin receptors in the brain: characterization and distribution. Science. 208:1980;1155-1156.
8. Moran T H, Robinson P, Goldrich M S, McHugh P R. Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res. 362:1986;175-179.
9. Dietl M M, Probst A, Placios J M. On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study. Synapse. 1:1987;169-183.
10. 125I]CCK8 probe. Neurochem Int. 110:1987;467-471.
11. Corp E S, McQuade J, Moran T H, Smith G P. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res. 623:1993;161-166.
12. 3H] L-364718 membrane binding assays. Mol Pharmacol. 36:1989;285-290.
13. 3H-MK-329. J Neurosci. 10:1990;1070-1081.
14. Wang X J, Wang X H, Han S. Cholecystokinin octapeptide antagonized opioid analgesia mediated by μ- and τ- but not δ-receptors in the spinal cord of the rat. Brain Res. 523:1990;5-10.
15. Morley J E. Appetite regulation by gut peptides. Annu Rev Nutr. 10:1990;383-395.
16. Katsuura G, Hirota R, Itoh S. Cholecystokinin- induced hypothermia in r at. Experientia. 30:1981;60.
17. Zetler G. Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) different from those of diazepam and haloperidol. Neuropharmacology. 20:1981;277-283.
18. Bourin M, Malinge M, Vasar E, Bradwejn J. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol. 10:1996;116-126.
19. Eur Neuropsychopharmacol. 6:1996;263-280.
20. Acosta G B. Administration of cholecystokinin sulphated octapeptide (CCK-8S) induces changes on rat amino acid tissue levels and on behavioral test for anxiety. Gen Pharmac. 31:1998;637-641.
21. Fekete M, Szipöcs I, Halmai L, Franczia P, Kardos A, Csonka E, Szánto-Fekete M, Telegdy G. Cholecystokinin and the central nervous system. Front Horm Res. 15:1987;175-251.
22. Van Ree J M, Gaffori O, De Wied D. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur J Pharmacol. 93:1983;63-78.
23. Katsuura G, Itoh S. Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats. Peptides. 7:1986;105-110.
24. Katsuura G, Itoh S. Prevention of experimental amnesia by peripherally administered cholecystokinin octapeptide in the rat. Drug Dev Res. 7:1986;269-276.
25. Itoh S, Takashima A, Katsuura G. Preventive effect of cholecystokinin octapeptide on scopolamine-induced memory impairment in the rat. Drug Dev Res. 12:1988;63-70.
26. Itoh S, Takashima A. Effect of cholecystokinin octapeptide antagonists on the extinction on an active avoidance task in the rat. Drug Dev Res. 17:1989;83-87.
27. Takashima A, Itoh S. Memory impairment induced by CCK-8 antagonists in passive avoidance response of the rat. Drug Dev Res. 18:1989;95-100.
28. Meziane H, Devigne C, Tramu G, Soumireu-Mourat B. Effect of anti-CCK-8 antiserum on acquisition and retrieval by mice in an appetitive task. Peptides. 14:1993;67-73.
29. Crawley J N, Cholecystokinin-dopamine interactions J N. Trends Pharmacol Sci. 1991;. p. 232-6.
30. Hamon M. Neuropharmacology of anxiety: perspectives and prospects. Pharmacol Sci. 15:1994;36-39.
31. Hommer D W, Stoner G, Crawley J N, Paul S M, Skirboll L R. Cholecystokinin-dopamine coexistence electrophysiological actions corresponding to cholecystokinin receptor subtype. J Neurosci. 10:1986;3039-3042.
32. Schneider L H, Alpert J E, Iversen S D. CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine stimulated behaviours. Peptides. 4:1986;749-752.
33. Kesner R P. Neurobiological views of memory. Martinez JL Jr, Kesner RP,. Learning, Memory. A Biological View. 1991;499-547 Academic Press, San Diego:
34. Wise R A, Rompre P P. Brain dopamine and reward. Annual Rev Psychol. 40:1989;191-225.
35. König J RF, Klippel R A. The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. 1963;Williams and Wilkins, Baltimore:
36. Breese G R, Traylor T D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol. 42:1971;88-89.
37. Ader R. Weijnen JAWM, Moleman P. Psychon Sci. 26:1972;125-130.
38. Agid Y, Javoy F, Glowinski J, Bouvet D, Sotelo C. Injection of 6-hydroxydopamine into the substantia nigra of the rat. Brain Res. 58:1973;291-301.
39. McGaugh J L, Dawson R. Modification of memory storage processes. Behav Sci. 16:1971;45-63.
40. Yeudall L T, Walley R E. Methylphenidate, amygdalectomy, and active avoidance performance in the rat. J Comp Physiol Psychol. 91:1977;1207-1219.
41. Schütz R A, Izquierdo I. Effect of brain lesions on rat shuttle behavior in four difference tests. Physiol Behav. 23:1979;97-105.
42. Eclancher F, Karli O. Effect of infant and adult amygdaloid lesions upon acquisition of two-way avoidance by the adult rat: influence of rearing conditions. Physiol Behav. 24:1980;887-893.
43. Nagel J A, Kemble E D. Effect of amygdaloid lesions on the performance of rats in four passive avoidance tasks. Physiol Behav. 17:1976;245-250.
44. Liang K C, McGaugh J L, Martinez J L, Jensen R AJ, Vasquez B J, Messing R B. Post-training amygdaloid lesions impair retention of an inhibitory avoidance response. Behav Brain Res. 4:1982;237-249.
45. Takashina K, Saito H, Nishiyama N. Preferential impairment of avoidanc e performances in amygdala- lesioned mice. Jpn J Pharmacol. 67:1995;107-115.
46. Gold P E, Hankins L L, Edwards R, Chester J, McGaugh J L. Memory interfer ence and facilitation with posttrial amygdala stimulation: Effect on memory varies with footshock level. Brain Res. 86:1975;509-513.
47. Kesner R P, Andrus R G. Amygdala stimulation disrupts the magnitude of reinforcement contribution to long-term memory. Physiol Psychol. 10:1982;55-59.
48. Pellegrino L. Amygdaloid lesions and behavioral inhibition in the rat. J Comp Physiol Psychol. 65:1968;483-491.
49. Grossman S P. Grossman L, Walsh L. J Comp Physiol Psychol. 88:1975;829-850.
50. Coover G D, Murison R, Jellestad F K. Subtotal lesions of the amygdala: the rostral central nucleus in passive avoidance and ulceration. Physiol Behav. 51:1992;795-803.
51. Kemble E D, Tapp J T. Passive and active avoidance performance following small amygdaloid lesions in rats. Physiol Behav. 3:1968;713-718.
52. Winnicka M M. 6-OHDA bilateral lesions to the central amygdala do not affect vasopressin improvement of recall in rats. Acta Neurobiol Exp. 56:1996;943-948.
53. Winnicka M M. 6-OHDA bilateral lesions to the amygdala abolish the memory enhancing effect of angiotensin II in rats. Pharmacol Res. 38:1998;53-58.
54. Winnicka M M, Boguszewicz J, Braszko J J. Lesions of central amygdala abolish angiotensin II improvement of recall in passive avoidance situation. Pol J Pharmacol Pharm. 40:1988;129-134.
55. Winnicka M M, Braszko J J, Wicśniewski K. 6-OHDA lesions to amygdala and hippocampus attenuate memory enhancing effect of the 3-7 fragment of angiote nsin II. Gen Pharmacol. 30:1998;801-805.
56. Jellestad F K, Markowska A, Bakke H K, Walther B. Behavioral effects afte r ibotenic acid, 6-OHDA and electrolytic lesions in the central amygdala nucleus of the rat. Physiol Behav. 37:1986;855-862.
57. Studler B, JM B, Simon H, Cesselin F, Legrand J C, Glowinski J, Tassin J P. Biochemical investigation on the localization of the cholecystokinin octapeptide in dopaminergic neurons originating from the ventral tegmental areas of the rat. Neuropeptides. 2:1981;131-139.
58. Crawley J N, Hommer D W, Skirboll L R. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat. Brain Res. 335:1985;337-341.
59. Fuxe K, Andersson K, Locatelli V, Agnati L F, Hökfelt T, Skirboll L, Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur J Pharmacol. 67:1980;329-331.